1. Phenylpropanoids

Droxidopa (Synonyms: L-DOPS; DOPS; SM5688)

Cat. No.: HY-13458 Purity: 99.58%
Data Sheet SDS Handling Instructions

Droxidopa(L-DOPS, SM5688) is a synthetic amino acid precursor which acts as a prodrug to the neurotransmitters norepinephrine (noradrenaline) and epinephrine (adrenaline); capable of crossing the protective blood–brain barrier IC50 value: Target: The acute administration of droxidopa in PVL and BDL rats caused a significant and maintained increase in arterial pressure and mesenteric arterial resistance, with a significant decrease of mesenteric arterial and portal blood flow, without changing portal pressure and renal blood flow [1].

For research use only. We do not sell to patients.
Droxidopa Chemical Structure

Droxidopa Chemical Structure

CAS No. : 23651-95-8

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
100 mg $140 In-stock
500 mg $420 In-stock
1 g   Get quote  
5 g   Get quote  

* Please select Quantity before adding items.

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

Droxidopa(L-DOPS, SM5688) is a synthetic amino acid precursor which acts as a prodrug to the neurotransmitters norepinephrine (noradrenaline) and epinephrine (adrenaline); capable of crossing the protective blood–brain barrier IC50 value: Target: The acute administration of droxidopa in PVL and BDL rats caused a significant and maintained increase in arterial pressure and mesenteric arterial resistance, with a significant decrease of mesenteric arterial and portal blood flow, without changing portal pressure and renal blood flow [1]. L-threo-dihydroxyphenyslerine (Droxidopa) is a pro-drug which has a structure similar to noradrenaline, but with a carboxyl group. It has no pressor effects in this form. It can be administered orally, unlike noradrenaline, and after absorption is converted by the enzyme dopa decarboxylase into noradrenaline thus increasing levels of the neurotransmitter which is identical to endogenous noradrenaline [2].

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT02071459 University Hospital, Toulouse Multiple System Atrophy February 2014 Phase 2|Phase 3
NCT02812147 St. Joseph's Hospital and Medical Center, Phoenix|Arizona State University, Tempe Parkinson Disease May 2016 Phase 2
NCT02624310 New York University School of Medicine HSAN Type IV January 2016 Phase 2
NCT03173781 Colorado Springs Neurological Associates|H. Lundbeck A/S Parkinson's Disease April 2016
NCT01354158 Bronx VA Medical Center|Chelsea Therapeutics Spinal Cord Injury|Hypotension May 2011 Phase 1
NCT01331122 Chelsea Therapeutics Gait Disorders, Neurologic April 2012 Phase 1|Phase 2
NCT01132326 Chelsea Therapeutics Primary Autonomic Failure|Dopamine Beta Hydroxylase Deficiency|Non-Diabetic Neuropathy|Neurogenic Orthostatic Hypotension January 2009 Phase 3
NCT00983814 Chelsea Therapeutics Attention Deficit Hyperactivity Disorder October 2009 Phase 2
NCT00977171 Chelsea Therapeutics Chronic Fatigue Syndrome|Orthostatic Hypotension|Neurally Mediated Hypotension|Neurogenic Orthostatic Hypotension July 2010 Phase 2
NCT01149629 Chelsea Therapeutics Symptomatic Neurogenic Orthostatic Hypotension July 2010 Phase 1
NCT01927055 Chelsea Therapeutics Symptomatic Neurogenic Orthostatic Hypotension|Parkinson's Disease|Multiple Systems Atrophy|Pure Autonomic Failure|Dopamine Beta Hydroxylase Deficiency November 2013 Phase 3
NCT00738062 Chelsea Therapeutics Neurogenic Orthostatic Hypotension|Non-Diabetic Autonomic Neuropathy|Multiple System Atrophy|Dopamine Beta Hydroxylase Deficiency January 2008 Phase 3
NCT02586623 Lundbeck Northera Ltd. Symptomatic Neurogenic Orthostatic Hypotension February 2016 Phase 4
NCT01176240 Chelsea Therapeutics Orthostatic Hypotension|Parkinson's Disease June 2010 Phase 3
NCT01323374 Chelsea Therapeutics Fibromyalgia January 2009 Phase 2
NCT01327066 Chelsea Therapeutics QTc Interval March 2011 Phase 1
NCT02897063 Vanderbilt University Medical Center Autonomic Failure|Pure Autonomic Failure|Multiple System Atrophy|Parkinson Disease|Orthostatic Hypotension September 2016 Phase 1
NCT00633880 Chelsea Therapeutics|Chiltern International Inc. Symptomatic Neurogenic Orthostatic Hypotension (NOH)|Non-diabetic Neuropathy|Primary Autonomic Failure|Dopamine Beta Hydroxylase Deficiency January 2008 Phase 3
NCT02066571 Henry Ford Health System Parkinson's Disease|Freezing of Gait|Cognitive Ability, General March 2015 Phase 2
NCT00657046 Chelsea Therapeutics Intradialytic Hypotension December 2007 Phase 2
NCT00782340 Chelsea Therapeutics|Chiltern International Inc. Symptomatic Neurogenic Orthostatic Hypotension (NOH)|Non-diabetic Neuropathy|Primary Autonomic Failure|Dopamine Beta Hydroxylase Deficiency September 2008 Phase 3
NCT01370512 Mayo Clinic Orthostatic Hypotension November 2011 Phase 2
NCT00889135 Vanderbilt University Dopamine Beta Hydroxylase (DBH) Deficiency September 2004
NCT00004478 Icahn School of Medicine at Mount Sinai|Office of Rare Diseases (ORD) Shy-Drager Syndrome|Orthostatic Hypotension March 1999
NCT01612078 TSH Biopharm Corporation Limited Orthostatic Hypotension June 2012 Phase 3
NCT03229174 William Ondo, MD|Lundbeck LLC|The Methodist Hospital System Parkinson Disease|Neurogenic Orthostatic Hypotension September 1, 2017 Phase 4
NCT01468259 Chelsea Therapeutics Renal Disease|End Stage Renal Disease October 2012 Phase 1
NCT00547911 National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC) Parkinson Disease|Multiple System Atrophy|Autonomic Nervous System Diseases October 2007 Phase 1|Phase 2
NCT02558972 New York Medical College|Lundbeck LLC Postural Tachycardia Syndrome (POTS)|Vasovagal Syncope (VVS)|Fainting September 2015 Phase 2
NCT03070730 Beth Israel Deaconess Medical Center|National Heart, Lung, and Blood Institute (NHLBI) Postural Orthostatic Tachycardia Syndrome|Orthostatic Intolerance August 15, 2011 Phase 1|Phase 2
NCT03115827 Vanderbilt University Medical Center|H. Lundbeck A/S|American Academy of Neurology Parkinson Disease April 18, 2017 Phase 4
NCT00581477 Vanderbilt University|Vanderbilt University Medical Center Autonomic Nervous System Diseases|Orthostatic Hypotension|Dopamine Beta-Hydroxylase Deficiency|Orthostatic Intolerance January 2004 Phase 3
View MoreCollapse
References
Molecular Weight

213.19

Formula

C₉H₁₁NO₅

CAS No.

23651-95-8

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

DMSO: 1.8 mg/mL (Need ultrasonic and warming)

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Droxidopa
Cat. No.:
HY-13458
Quantity: